Search results for " TUMOR NECROSIS FACTOR"

showing 10 items of 110 documents

A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Di…

2019

Background and aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naive and non-naive patients. Results A total of 632 patients [735 total treatments] were included. Among naive patients, a cli…

0301 basic medicineAdultMalemedicine.medical_specialtyInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseGastrointestinal AgentsInternal medicinemedicineAdalimumabHumansYoung adultSicilypropensity scoreCrohn's diseasebusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabGeneral MedicineOdds ratiomedicine.diseaseAdalimumab; infliximab; propensity score; Adalimumab; Adult; Crohn Disease; Female; Gastrointestinal Agents; Humans; Infliximab; Male; Propensity Score; Sicily; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultInfliximab030104 developmental biologyTreatment OutcomeCohortPropensity score matching030211 gastroenterology & hepatologyFemalebusinessinfliximabmedicine.drug
researchProduct

A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development.

2017

Summary Concomitant hepatocyte apoptosis and regeneration is a hallmark of chronic liver diseases (CLDs) predisposing to hepatocellular carcinoma (HCC). Here, we mechanistically link caspase-8-dependent apoptosis to HCC development via proliferation- and replication-associated DNA damage. Proliferation-associated replication stress, DNA damage, and genetic instability are detectable in CLDs before any neoplastic changes occur. Accumulated levels of hepatocyte apoptosis determine and predict subsequent hepatocarcinogenesis. Proliferation-associated DNA damage is sensed by a complex comprising caspase-8, FADD, c-FLIP, and a kinase-dependent function of RIPK1. This platform requires a non-apop…

0301 basic medicineGenome instabilityMaleliver; Hepatocellular carcinoma; DNA damage response; replication stress; apoptosisCancer ResearchDNA RepairCarcinogenesisFas-Associated Death Domain ProteinApoptosisurologic and male genital diseasesDNA damage responseDna Damage Response ; Apoptosis ; Hepatocellular Carcinoma ; Liver ; Replication StressHistonesMice0302 clinical medicineRisk FactorsFADDPhosphorylationCellular SenescenceCaspase 8biologyLiver Neoplasmshepatocellular carcinomaLiver regeneration3. Good healthHistoneOncologyReceptors Tumor Necrosis Factor Type I030220 oncology & carcinogenesisReceptor-Interacting Protein Serine-Threonine KinasesFemalebiological phenomena cell phenomena and immunityCell agingCarcinoma HepatocellularDNA damageDNA repairreplication stressCaspase 8liverArticleGenomic Instability03 medical and health sciencesAnimalsHepatectomyHumansCrosses GeneticCell ProliferationJNK Mitogen-Activated Protein KinasesCell BiologyLiver Regeneration030104 developmental biologyImmunologyChronic Diseasebiology.proteinCancer researchHepatocytesMyeloid Cell Leukemia Sequence 1 ProteinDNA Damage
researchProduct

Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion

2015

Activation of TNFR2 with a novel agonist expands T reg cells in vivo and protects allo-HCT recipients from acute GvHD while sparing antilymphoma and antiinfectious properties of transplanted donor T cells.

0301 basic medicineInterleukin 2medicine.medical_treatmentImmunologyGraft vs Host DiseaseMice Inbred Strainschemical and pharmacologic phenomenaHematopoietic stem cell transplantationBiologyT-Lymphocytes RegulatoryArticleMice03 medical and health sciencesInterleukin 21immune system diseaseshemic and lymphatic diseasesmedicineAnimalsReceptors Tumor Necrosis Factor Type IIImmunology and AllergyCytotoxic T cellddc:610Research Articlesintegumentary systemMyeloid-Derived Suppressor CellsHematopoietic Stem Cell TransplantationFOXP3hemic and immune systemsmedicine.diseaseLeukemiaddc:57030104 developmental biologysurgical procedures operativeAcute DiseaseImmunologyMyeloid-derived Suppressor CellInterleukin-2FemaleTumor necrosis factor receptor 2medicine.drug
researchProduct

Cutaneous manifestations associated with anosmia, ageusia and enteritis in SARS-CoV-2 infection - a possible pattern? Observational study and review …

2021

BACKGROUND: The cutaneous manifestations of coronavirus disease 2019 (COVID-19) have been covered insufficiently in the literature. METHODS: Thirty-nine patients admitted to the study hospital with confirmed COVID-19 who experienced various skin manifestations during hospitalization or in the convalescence period, were analysed retrospectively. RESULTS: Thirty-nine patients with COVID-19, admitted to the study hospital between 23 March and 12 September 2020, had intra-infectious rash or lesions of cutaneous vasculitis during convalescence. The most common cutaneous manifestations of COVID-19 were erythematous and erythematous papular rash. Twenty-seven of the 39 patients had anosmia (69.2%)…

0301 basic medicineMaleACE2 angiotensin‐converting enzyme 2ErythemaReceptor expressionTNF Tumor Necrosis Factor alphaInfectious and parasitic diseasesRC109-216B cells B lymphocyteslesions0302 clinical medicine030212 general & internal medicineskin and connective tissue diseasesCOVID coronavirus disease 2019media_commonEnterocolitisNK cells Natural killer cellsConvalescenceGeneral MedicineRashEnteritisInfectious DiseasesFemalemedicine.symptomCD Cluster of differentiationIHC immunohistochemistryMicrobiology (medical)medicine.medical_specialtyRT real-time reverse transcriptase–polymerase chain reactionmedia_common.quotation_subjectAnosmia030106 microbiologyAnosmiaSkin DiseasesArticle03 medical and health sciencesmedicineHumansbiopsySARS Severe acute respiratory syndrome coronavirus 2HE Hematoxylin and eosin stainRetrospective Studiescutaneous manifestationsbusiness.industrySARS-CoV-2SARS-CoV-2 infectionCOVID-19Ageusiamedicine.diseaseDermatologyPneumoniaIL 1 Interleukin 1IFN-γ Interferon γbusinessAgeusiaInternational Journal of Infectious Diseases
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFα

2017

Amyotrophic lateral sclerosis (ALS) is considered a multifactorial, multisystem disease in which inflammation and the immune system play important roles in development and progression. The pleiotropic cytokine TNFαis one of the major players governing the inflammation in the central nervous system and peripheral districts such as the neuromuscular and immune system. Changes in TNFαlevels are reported in blood, cerebrospinal fluid, and nerve tissues of ALS patients and animal models. However, whether they play a detrimental or protective role on the disease progression is still not clear. Our group and others have recently reported opposite involvements of TNFR1 and TNFR2 in motor neuron dea…

0301 basic medicinePathologymedicine.medical_specialtyAmyotrophic Lateral Sclerosis; Animals; Humans; Motor Neurons; T-Lymphocytes Regulatory; Tumor Necrosis Factor-alphamedicine.medical_treatmentT-LymphocytesCentral nervous systemImmunologyAmyotrophic lateral sclerosis inflammation TNFαInflammationReview ArticleT-Lymphocytes Regulatory03 medical and health sciences0302 clinical medicineImmune systemCerebrospinal fluidImmunology; Cell BiologyTNFαlcsh:PathologyMedicineAnimalsHumansAmyotrophic lateral sclerosisMotor Neuronsbusiness.industryTumor Necrosis Factor-alphaAmyotrophic Lateral SclerosisCell BiologyMotor neuronmedicine.diseaseRegulatory3. Good health030104 developmental biologymedicine.anatomical_structureCytokineinflammationImmunologyTumor necrosis factor alphamedicine.symptombusiness030217 neurology & neurosurgerylcsh:RB1-214
researchProduct

Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.

2017

The mechanisms that regulate cell death and inflammation play an important role in liver disease and cancer. Receptor-interacting protein kinase 1 (RIPK1) induces apoptosis and necroptosis via kinase-dependent mechanisms and exhibits kinase-independent prosurvival and proinflammatory functions. Here, we have used genetic mouse models to study the role of RIPK1 in liver homeostasis, injury, and cancer. While ablating either RIPK1 or RelA in liver parenchymal cells (LPCs) did not cause spontaneous liver pathology, mice with combined deficiency of RIPK1 and RelA in LPCs showed increased hepatocyte apoptosis and developed spontaneous chronic liver disease and cancer that were independent of TNF…

0301 basic medicineProgrammed cell deathLiver tumorCell SurvivalNecroptosisMice TransgenicBiologyChronic liver diseaseProinflammatory cytokine03 medical and health sciencesLiver diseaseMiceLiver Neoplasms ExperimentalmedicineAnimalsDiethylnitrosamineKinase activityTranscription Factor RelAGeneral Medicinemedicine.disease3. Good healthNeoplasm Proteins030104 developmental biologymedicine.anatomical_structureCell Transformation NeoplasticReceptors Tumor Necrosis Factor Type IHepatocyteReceptor-Interacting Protein Serine-Threonine KinasesCancer researchHepatocytesSignal TransductionResearch ArticleThe Journal of clinical investigation
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A S…

2020

This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. Patients’ data were collected retrospectively and then analyzed according to age groups (disease onset before or after 16 years) and genotype (high penetrance (HP) and low penetrance (LP) TNFRSF1A gene variants). Pediatric- and adult-onset were reported, respectively, in 44 and 36 patients; HP and LP variants were found, respectively, in 32 and 44 cases. A positive family history for recurrent fever was reported more frequently in the pediatric group than in the adult group (p<0.05…

0301 basic medicinemyalgiaMaleAbdominal painSettore MED/16 - REUMATOLOGIATNFRSF1AGene mutationGastroenterology0302 clinical medicinePathologyMedicineRB1-214PericarditisChildPrognosisPenetranceInflamacióFamilial Mediterranean FeverAIDA networkEstudi de casosReceptors Tumor Necrosis Factor Type IChild PreschoolAutoinflammationFemalemedicine.symptomResearch ArticleAdultmedicine.medical_specialtyArticle SubjectAdolescentGenotypetumor necrosis factorImmunologyContext (language use)Asymptomatic03 medical and health sciencesYoung AdultInternal medicineAnimalsHumansRetrospective Studies030203 arthritis & rheumatologyInflammationbusiness.industrytumor necrosis factor TRAPS AIDA networkTumor Necrosis Factor-alphaInfantTRAPSCell BiologyMyalgiaBiological productmedicine.disease030104 developmental biologyMutationCase studiesbusinessKidney diseaseMediators of Inflammation
researchProduct

Splenic Littoral Cell Hemangioendothelioma in a Patient With Crohn's Disease Previously Treated With Immunomodulators and Anti-TNF Agents: A Rare Tum…

2011

Th e risk of malignancy in Crohn ’ s disease (CD) has been well described. Moreover, immunomodulators, uch as azathioprine (AZA) and 6-mercaptopurine (6-MP), and biological agents, such as infl iximab and adalimumab, may promote carcinogenesis ( 1 – 3 ). Splenic littoral cell tumors are recently described tumors of vascular origin composed of endothelial cells, with typical microscopic and immunohistochemical features of splenic sinus lining cells ( 4 ). Clinical findings are not specific, and outcome is unpredictable but usually benign, although a few cases with a malignant behavior have been reported ( 5,6 ). We report a 58-year-old Caucasian man with a long history of ileocolonic CD.

6-MercaptopurineMalePathologymedicine.medical_specialtyColonic Diseasemedicine.medical_treatmentAzathioprineSplenic NeoplasmHemangioendotheliomaHemangiomaImmunosuppressive AgentImmunocompromised HostImmunologic FactorCrohn Disease6-Mercaptopurine; Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemangioma; Humans; Ileal Diseases; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Splenic Neoplasms; Tumor Necrosis Factor-alpha; Immunocompromised Host; GastroenterologyAzathioprineGastrointestinal AgentMedicineGastrointestinal agentCrohn's diseaseHepatologyTumor Necrosis Factor-alphabusiness.industryGastroenterologyImmunosuppressionMiddle Agedmedicine.diseaseSplenic NeoplasmHemangioendotheliomaImmunologyIleal DiseaseTumor necrosis factor alphaHemangiomabusinessHumanmedicine.drugAmerican Journal of Gastroenterology
researchProduct